mIDH1 cholangiocarcinoma

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

mIDH1 cholangiocarcinoma

Apr 4, 2025, 20:29 | Science

Gaëlle Saint-Hilary: Benefit-risk assessment of ivosidenib vs. placebo in mIDH1 cholangiocarcinoma

Gaëlle Saint-Hilary, CEO, Statistical methodologist at Saryga, shared a post on LinkedIn about a paper…

All: 1 Posts: 1 - 100

'

Martin Makary Becomes the 27th FDA Commissioner

'

OncoBillionaires of 2025: The Titans Behind the Cancer Revolution

'

Fellows of ASCO (FASCO) Recipients For Last Quarter

'

Val Kilmer Dies at 65: The Actor Who Fought Throat Cancer and Inspired Generations

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023